| 5.84 0.08 (1.39%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.58 | 1-year : | 8.85 |
| Resists | First : | 6.48 | Second : | 7.58 |
| Pivot price | 5.91 |
|||
| Supports | First : | 5.57 | Second : | 5.01 |
| MAs | MA(5) : | 5.92 |
MA(20) : | 5.87 |
| MA(100) : | 5.22 |
MA(250) : | 6.17 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 21 |
D(3) : | 29.7 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 12.68 | Low : | 3.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SER ] has closed above bottom band by 34.0%. Bollinger Bands are 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.16 - 6.19 | 6.19 - 6.21 |
| Low: | 5.68 - 5.71 | 5.71 - 5.74 |
| Close: | 5.79 - 5.84 | 5.84 - 5.89 |
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Tue, 17 Jun 2025
Juvenescence Lands $76M Funding and M42 Partnership to Transform Drug Development in Abu Dhabi - Stock Titan
Tue, 17 Jun 2025
UPDATED: Serina Therapeutics Congratulates Juvenescence - GlobeNewswire
Tue, 17 Jun 2025
Serina Therapeutics Congratulates Juvenescence on Securing $150 Million Series B Financing and Strategic Alliance with M42 - Nasdaq
Tue, 17 Jun 2025
$150M Biotech Deal: Juvenescence Partners With M42 to Launch AI-Powered Drug Hub in Abu Dhabi - Stock Titan
Mon, 09 Jun 2025
Registration Is Now Open For Tribe Public’s CEO - GlobeNewswire
Thu, 22 May 2025
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 2.94e+006 (%) |
| Held by Institutions | 58.1 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.27e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 356.79 |
| Profit Margin | -220.9 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 580.3 % |
| Return on Equity (ttm) | -45.3 % |
| Qtrly Rev. Growth | 3.17e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 27520 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|